Literature DB >> 32460144

Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions.

Rezvan Noroozi1, Wojciech Branicki1, Krzysztof Pyrc1, Paweł P Łabaj1, Ewelina Pospiech1, Mohammad Taheri2, Soudeh Ghafouri-Fard3.   

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in early 2020. The infection has been associated with a wide range of clinical symptoms. In the severely affected patients, it has caused dysregulation of immune responses including over-secretion of inflammatory cytokines and imbalances in the proportion of naïve helper T cells, memory helper T cells and regulatory T cells. Identification of the underlying mechanism of such aberrant function of immune system would help in the prediction of disease course and selection of susceptible patients for more intensive cares. In the current review, we summarize the results of studies which reported alterations in cytokine levels and immune cell functions in patients affected with SARS-CoV-2 and related viruses.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokine; Immune cells; SARS-CoV

Mesh:

Substances:

Year:  2020        PMID: 32460144      PMCID: PMC7241386          DOI: 10.1016/j.cyto.2020.155143

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


Introduction

Firstly, identified in an outbreak in Wuhan city of China, the novel coronavirus disease 2019 (COVID-19) has caused a global pandemic in early 2020. Alternatively named as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus has been shown to induce various clinical manifestation in hosts ranging from asymptomatic conditions to severe symptoms including respiratory failure, shock, or multiorgan system dysfunction [1]. Identification of IgM and IgG antibodies in the affected persons implies the development of immunity against SARS-CoV-2 [2], [3], [4]. However, the virus might also induce dysregulation of immune responses in susceptible individuals as demonstrated by the decreased lymphocytes counts especially T cells, increased leukocytes counts and neutrophil–lymphocyte-ratio and other imbalances in the population of immune cells. Moreover, severely affected patients have shown raised concentrations of infection-related markers and over-secretion of inflammatory cytokines. Notably, this condition has been accompanied by a significant increase in the proportion of naïve helper T cells while reduction in memory helper T cells and regulatory T cells [5]. Based on the importance of immune responses in the determination of course of infection and the related complications, we performed a literature search to find the reported dysregulations in the levels of cytokines and immune cells in patients infected with SARS-CoV-19 and related viruses.

SARS-CoV-2

A recent study in Chinese patients affected with SARS-CoV-2 has shown elevated plasma concentrations of IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, basic FGF, GCSF, GMCSF, IFN-γ, IFN-γ-induced protein (IP)-10, monocyte chemotactic protein 1 (MCP1), MIP1A, MIP1B and TNF-α in both patients needed ICU admission and non-ICU patients compared with healthy controls at initial assessment. Notably, author reported significant over-production of IL-2, IL-7, IL-10, GCSF, IP-10, MCP1, MIP1A, and TNF-α in ICU patients compared with other group of SARS-CoV-2 infected persons [6]. Another study has demonstrated associations between severity of SARS-CoV-2 infection and levels of IL-2R, IL-6, IL-8, IL-10 and TNF-α. Moreover, disease severity was associated with both WBC and lymphocyte counts as well as quantities of neutrophils and eosinophils. Authors have suggested the IL-2R level > 793.5U/mL, WBC > 9.5*10^9/L or neutrophil count > 7.305*10^9/L among parameters that indicate progression of SARS-CoV-19 infection to critical conditions. Thus, inflammatory responses were shown to be correlated with the severity of SARS-CoV-19. Besides, IL-6, TNF-α and IL-8 have been suggested as therapeutic targets [7]. A longitudinal study of cytokine levels and lymphocyte count in affected patients has revealed remarkable and continuous decreases in lymphocyte counts but elevations in neutrophil counts in severely infected cases compared with mild cases. Additionally, severely affected individuals had substantial reductions in T cells population, particularly CD8 + T cells, and upsurge in IL-6, IL-10, IL-2 and IFN-γ levels. Notably, T cell counts and cytokine concentrations in severe SARS-CoV-2 infected patients who stayed alive gradually returned to their levels in the mild cases. The most significant prognostic marker to show the course of infection has been the neutrophil-to-CD8 + T cell ratio [8]. IL-6 has also been among the up-regulated infection-related markers in the serum of patients with SARS-CoV-2 pneumonia [9]. Another study has demonstrated significant decrease in lymphocyte subsets both in severe and mild groups of patients with SARS-CoV-2 infection. Reduction in CD8 + T cells and increase in IL-6 levels were more prominent in the severely affected patients. Moreover, significant differences were detected between the severe and mild groups in CD4 + T, CD8 + T, IL-6 and IL-10 [7].

SARS-CoV

Cellular immune responses to SARS-CoV infection have been previously assessed in an animal study. Animals were exposed to the virus through an intranasal route. Such viral administration resulted in induction of pneumonia which was accompanied by over-production of TNF-α, IL-6, CXCL10, CCL2, CCL3, and CCL5. Notably, increased cytokine and chemokine levels were associated with relocation of NK cells, macrophages, and plasmacytoid dendritic cells (pDC) into the lungs. The viral clearance was accompanied by another round of cytokine and chemokine release and an inflow of T lymphocytes occurred. Depletion studies showed the essential role of CD4 + but not CD8 + T cells in reduction of immune-mediated interstitial pneumonitis and enhancement of elimination of SARS-CoV from the lungs [10]. An in vitro study has shown insignificant induction of IFN-β expression in SARS-CoV infected macrophages, while up-regulation of CXCL10/IFN-γ-inducible protein 10 and CCL2/monocyte chemotactic protein 1 [11]. Wong et al. have assessed a number of cytokines and chemokines in patients affected with SARS. They detected significant increase in Th1 cytokine IFN-γ, inflammatory cytokines IL-1, IL-6 and IL-12, and some chemokines such as IL-8, MCP-1 and IP-10. Levels of chemokines were significantly decreased after corticosteroid therapy. They concluded induction of Th1 cell-mediated immune response in patients. This observation was associated with induction of monocytes/macrophages and neutrophils [12]. In another study in the pediatric setting, Ng et al. have demonstrated significant increase in circulating IL-1β concentrations. Yet, IL-6 and TNF-α cytokines were slightly increased at the primary phase of the disease [13]. Zhang et al. did not detect any significant difference IL-1 and TNF-α levels between normal controls, patients with SARS, severe SARS or those with SARS in convalescence. IL-6 levels were higher in SARS particularly those with severe SARS course. Yet, IL-6 levels were not different between convalescent patients and healthy control, indicating the presence of a positive correlation between the serum IL-6 levels and severity of the disorder. On the other hand, IL-8 and TGF-β levels were negatively correlated with SARS severity. IFN-γ and IL-4 concentrations were reduced, whereas IL-10 concentrations were elevated in convalescent SARS patients. Taken together, various immunoregulatory conditions are present during and subsequent to SARS infection [14].

Middle east respiratory syndrome coronavirus (MERS-CoV)

Lau et al. have assessed transcript levels of TNF-α, IL-1β, IL-6, IL-8, IFN-β, MCP1, TGF-β and IP-10 in cell lysates of polarized airway epithelial Calu-3 cells infected with MERS-CoV or SARS-CoV. MERS-CoV induced higher levels of IL-1β, IL-6 and IL-8, while lower levels of TNF-α, IFN-β and IP-10 compared with SARS-CoV. Their experiments confirmed the diminished induction of innate immunity and postponed proinflammatory cytokine production by MERS-CoV [15]. Kim et al. have reported higher neutrophil counts in severe MERS-CoV compared with mild cases. Moreover, IL-6 and CXCL-10 levels were higher in severe cases compared with mild cases. Besides, they could not detect IFN-α response in mild cases [16]. Zhou et al. have shown ability of MERS-CoV but not SARS-CoV in replication in monocyte-derived macrophages. MERS-CoV induced remarkably elevated concentrations of IL-12, IFN-γ, and chemokines compared with SARS-CoV [17]. Mahallawi et al. have demonstrated a noticeable pro-inflammatory Th1 and Th17 response in patients affected with MERS-CoV. These patients had elevated levels of IFN-γ, TNF-α, IL-15 and IL-17 compared to controls. Totally, cytokines profiles indicated an obvious pro-inflammatory immune reactions in the acute course of MERS-CoV infection [18].

Influenza

Pirhonen et al. have demonstrated induction of trivial amounts of IL-1β or IL-18 in influenza virus-infected monocytes, while GM-CSF-differentiated macrophages secreted high amounts of these cytokines. In vitro experiments indicated that the role of cellular differentiation in the aptitude of monocytes/macrophages to secrete IL-1β and IL-18 following exposure with virus infections [19]. In addition, Ramos et al. have reported lower monocyte counts and a marginally lower median level of IL-6 in patients infected with influenza compared with the control group [20]. Table 1 summarizes the results of studies which reported altered cytokine levels and immune functions in patients with SARS-CoVs and influenza infections and related conditions.
Table 1

Summary of studies which reported altered cytokine levels and immune functions in patients with SARS-CoV infections and related conditions.

DiseaseCase/ControlSampleFindingCommentRef
CytokinesImmune cells
SARS-CoV-240 cases:13 Severe, 27 mildBloodElevated IL-6, IL-10, IL-2, IFN-γ levels in severe casesIncreased neutrophil, decreased lymphocyte counts esp. CD8 + T in severe casesN8R ratio as a as a prognostic factor[8]
99 casesBloodIncreased IL-6Increased leucocytes, neutrophils, decreased lymphocytes[9]
41 cases: 13 ICU/ 28 non-ICU patientsPlasmaElevated IL-10, IL-2, IL-7, GSCF, IP10, MCP1, MIP1A, and TNFα in ICU patients[3]
100 cases: 34 mild, 34 severe, 32 criticalBloodA significant association between IL and 6, IL-10, IL2R, IL-8, TNFα, CRP, ferroprotein, procalcitonin, and disease severityA significant association between WBC, lymphocyte, neutrophil and eosinophil counts and disease severityIL-6, TNFα, IL-8 as promising therapeutic targets[7]
53 cases:34 severe, 19 mildPlasmaAssociation of IP-10, MCP-3, IL-1ra with disease severity[6]
123 cases:21 severe, 102 mildBloodElevated IL-6 and IL-10 in severe NCPDecreased CD4 + T, CD8 + T in severe NCPT cell subsets and cytokines as predictive factors for severity.[7]
MERSCase report of a child with influenza associated MERSCSF and serumElevated IL-10 and IFN‐γ in early phase in CSF[21]
MERS infected cells/SARS infected cellsCalu-3 cellsHigher IL-1β, IL-6 and IL-8 induced by MERS, higher TNF-α, IFN-β and IP-10 induced by SARS-CoVDelayed proinflammatory cytokine induction by MERS-CoV[15]
MERS-infected MDMs/SARS infected MDMsMDM cellsElevated TNF-α, Il-10 in both cells, higher MERS induced IL-8, IL-12, IFN-γ, IP-10/CXCL-10, MCP1/CCL-2, MIP-1α/CCL-3, RANTES/CCL-5None of the viruses were able to induce IFN-α and IFN- β.[17]
17 casesSerumElevated IL-6 and CXCL-10Elevated serum levels of IL-6 and CXCL-10 in severe patients[16]
7/13PlasmaElevated IFN-γ, TNF-α, Il-10, IL-15 and IL-17MERS induced Th1 and Th17 cytokine profile[18]
14 cases: 4 groups based on severityPlasmaElevated IFN-α, G-CSF, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IL-15, IL-17A, IFN-γ, TGF-β, MCP-1 (CCL2), IP-10 (CXCL10), MDC (CCL22), RANTES (CCL5), IL-8 (CXCL8), MIP-1 (CCL3), Eotaxin (CCL11), and GRO (CXCL1)Increased lymphocytes, neutrophils, leukocytes and monocytescountsIL-10, IL-15, TGF-β, and EGF were correlated with disease severity[22]
SARS8 children before corticosteroids therapy/after 1–2 days/after 7–10 daysPlasmaElevated IL-1β -before and 7–10 days after therapy,decreased IL-10, IL-6, IL-8TNF-α was not significantly elevated thus TNF-α monoclonal antibody was not recommended.[13]
SARS infected cells / cells infected with RSV, FluAV, and hPIV2.Caco2 cellsInduced high levels of IL-6, IFN-β, TLR4, TLR9[23]
88 cases 51 Ab positive/37 Ab negativeSerumElevated IFN- γ, IL-18, TGF- β, IL-6, IP-10, MCP-1, MIG, and IL-8IFN- γ induced cytokine storm after viral infection[24]
20 casesPlasmaElevated IL-1, IL-6, IL-8,IL-12, IFN-γ, MCP-1, IP-10Accumulation of monocytes/macrophages and neutrophilsTh1 cell‐mediated immunity and hyperinnate inflammatory response in SARS.[12]
228 casesSerumElevated IL-6, decreased IL-8 and TGF-βElevated IFN-γ, IL-4 and decreased IL-10 only in convalescent SARS patients.[14]
61 cases:initial stage, peak stage, remission,recovery stage / 44 Healthy controlSerumElevated IL-6, IL-8, TNF-α, IL-16, TGF-β1, decreased IL-18The mean concentration of IL-13 gradually decreased from initial stage to recovery.[25]
InfluenzaHMCIL-1β mRNA expression was induced by influenza A and Sendai viruses.Virus induced IL-1β and IL-18 expression and activation is related to cellular differentiation and caspase-1-dependent pathway.[19]
19 casesNasal lavage fluid, plasma, serumElevated IL-6, IL-8, IFN-α[26]
Human primary alveolar and bronchial epithelial cellsIP-10, IFN-β, RANTES, IL-6[27]
77/17Nasal lavage fluidLower IL-6Lower monocyte countsPro-inflammatory cytokines levels were not elevated in patients with pneumonia.[20]
ARDS51 casesat the time of ECMO installation/ 6  h laterPlasmaElevated IL-10 and IL-8 levelsHigher Treg, CD14 + CD16+, CD14 + TLR4 + cell counts in survivorsIL-10 levels predict ICU mortality.[28]
300/300PlasmaHigher TNF-α, IL-6 levels in patientsFunctional polymorphisms in TNF-α, IL-6, MyD88 are associated with ARDS mortality.[29]
Pneumonia15 severe/15 non-severe CAPBloodElevated IL-6, IL-10, IL-8, CRP levelsIL-6 sharp decrease was associated with response to empirical antibacterial treatment by day 3.[30]
Septic shockEndotoxin-stimulated septic monocytes/normal monocytesSerumElevated IL-10, attenuated TNF-α in septic serumThe persistent release of IL-10 leads to impaired proinflammatory cytokine release and the immune dysfunction in septic shock.[31]
16 septic shock/ 11 circulatory shockPlasmaMore increased IL-10 in septic shock casesThe production of the IL-10 positively correlates with the intensity of the inflammatory response in septic shock.[32]
Febrile illness464 cases431 survived/ 33 deadPlasmaHigher IL-10 and lower TNFα in patients who diedIL-10 to TNFα ratio was associated with mortality of CAI.[33]

Severe acute respiratory syndrome coronavirus 2, Neutrophil-to-CD8 + T cell ratio (N8R), 2019 novel coronavirus pneumonia (NCP), Human Macrophage Cell (HMC), human monocyte–derived macrophages (MDMs), human monocyte-derived dendritic cells (DCs), SARS sera antibody (Ab positive), cerebrospinal fluid (CSF), Acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO), community-acquired pneumonia (CAP), community-acquired infection (CAI).

Summary of studies which reported altered cytokine levels and immune functions in patients with SARS-CoV infections and related conditions. Severe acute respiratory syndrome coronavirus 2, Neutrophil-to-CD8 + T cell ratio (N8R), 2019 novel coronavirus pneumonia (NCP), Human Macrophage Cell (HMC), human monocyte–derived macrophages (MDMs), human monocyte-derived dendritic cells (DCs), SARS sera antibody (Ab positive), cerebrospinal fluid (CSF), Acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO), community-acquired pneumonia (CAP), community-acquired infection (CAI).

Discussion

Immune responses have indispensable functions in the determination of course of SARS-CoV infection. Dysregulation of cytokine levels have been demonstrated in almost all patients with this infection. Moreover, evident differences have been reported in the levels of several cytokines between severely affected patients and those with moderate or mild symptoms [6]. Identification of these aberrant reactions not only helps in recognition of patients who are predisposed to severe complications, but also would specify those would benefit from immune-modulating therapies. Due to the insufficiency of data on SARS-CoV-2, assessment of immune responses in other related disorders would provide a scheme permitting the anticipation of immune-related events which occur in the course of this novel infection. Yet, any of these viruses might exert some specific effects in the host. This speculation has been supported by an in vitro study on expression signatures of macrophages infected with SARS-CoV, human coronavirus 229E, and influenza A (H1N1) virus. Authors have reported slight or no induction of IFN-β in SARS-CoV-infected macrophages. Yet, expression of this cytokine was induced in the macrophages infected with human coronavirus 229E and influenza A virus [11]. Moreover, there were significant differences in the pattern of cytokine induction between SARS-CoV and MERS-CoV [15]. It is worth mentioning that although low-level of SARS-CoV productive infection has been demonstrated in human monocytes/macrophages, these viruses have been identified in phagolysosomes but not on the cell surface implying absence of specific receptors for SARS entrance on macrophages [34]. Low efficiency of macrophage infections by this virus and production of IFN-α by these cells might be involved in the restriction of the infection in human subjects [34]. Similarly, SARS-CoV-2 cannot replicate in macrophages possibly due to lack of ACE2 expression (https://www.genecards.org/cgi-bin/carddisp.pl?gene=ACE2). Banerjee et al. have assessed an extensive spectrum of human immune cells for productive infection with this virus and verified lack of permissivity of human primary peripheral blood mononuclear cells to this virus [35]. Others have shown infection of human macrophages by SARS-CoV via an IgG-mediated antibody-dependent enhancement mechanism [36]. The significant increase in plasma IL-1β concentrations in SARS patients have also implied the presence of a selective caspase-1-dependent route in induction of macrophages that are infected with this virus [13]. Animal studies have previously highlighted the role of CD4 + T cells in the inhibition of immune-mediated interstitial pneumonitis, enhancement of SARS-CoV elimination from the lungs, production of neutralizing antibody and cytokines and recruitment of lymphocytes to the lung [10]. However, there is no comprehensive data about the role of these cells in the course of SARS-CoV-2 infection. Yet, as noted by most of studies, the level of lymphopenia and upsurge of proinflammatory cytokines are determinants of severe SARS-CoV-2 infection [8]. Lymphopenia in severe cases include both CD4 + T and CD8 + T subsets [7]. Meanwhile, elevated levels of IL-6 and IL-10 has been suggested as factors that predict severe course of the disorder [7]. Taken together, the data presented above show some levels of similarity in the levels of proinflammatory cytokines particularly IL-6 and IL-10 as well as T cell subsets among different coronaviruses which indicate the role of these cytokines in the pathogenesis of infection-related complications. Future studies are needed to find the practical modalities to defend these aberrant responses and improve the clinical outcomes.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  28 in total

Review 1.  Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.

Authors:  Benjamin M Liu; Harry R Hill
Journal:  J Interferon Cytokine Res       Date:  2020-12       Impact factor: 2.607

2.  A study of differential circRNA and lncRNA expressions in COVID-19-infected peripheral blood.

Authors:  Yingping Wu; Tiejun Zhao; Riqiang Deng; Xiaoping Xia; Bin Li; Xunzhang Wang
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

Review 3.  Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity.

Authors:  Rebecca A Elsner; Mark J Shlomchik
Journal:  Immunity       Date:  2020-12-15       Impact factor: 31.745

Review 4.  Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.

Authors:  Ivo Udovicic; Ivan Stanojevic; Dragan Djordjevic; Snjezana Zeba; Goran Rondovic; Tanja Abazovic; Srdjan Lazic; Danilo Vojvodic; Kendrick To; Dzihan Abazovic; Wasim Khan; Maja Surbatovic
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

5.  SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System?

Authors:  Elisabetta Meacci; Mercedes Garcia-Gil; Federica Pierucci
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

6.  Relative expression of proinflammatory molecules in COVID-19 patients who manifested disease severities.

Authors:  Shireen Nigar; Sm Tanjil Shah; Md Ali Ahasan Setu; Sourav Dutta Dip; Habiba Ibnat; M Touhidul Islam; Selina Akter; Iqbal Kabir Jahid; M Anwar Hossain
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

7.  Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI.

Authors:  Fabian Bohländer; Dennis Riehl; Sabrina Weißmüller; Marcus Gutscher; Jörg Schüttrumpf; Stefanie Faust
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

8.  Evaluation of expression of VDR-associated lncRNAs in COVID-19 patients.

Authors:  Mohammad Taheri; Lina Moallemi Rad; Bashdar Mahmud Hussen; Fwad Nicknafs; Arezou Sayad; Soudeh Ghafouri-Fard
Journal:  BMC Infect Dis       Date:  2021-06-19       Impact factor: 3.090

9.  Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals.

Authors:  Swapnil Mahajan; Vasumathi Kode; Keshav Bhojak; Coral Karunakaran; Kayla Lee; Malini Manoharan; Athulya Ramesh; Sudheendra Hv; Ankita Srivastava; Rekha Sathian; Tahira Khan; Prasanna Kumar; Ravi Gupta; Papia Chakraborty; Amitabha Chaudhuri
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

Review 10.  Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.

Authors:  Marisa Market; Leonard Angka; Andre B Martel; Donald Bastin; Oladunni Olanubi; Gayashan Tennakoon; Dominique M Boucher; Juliana Ng; Michele Ardolino; Rebecca C Auer
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.